Meet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 3

Featuring perspectives from Dr Sara A Hurvitz, including the following topics: Introduction: Antibody-Drug Conjugates in Breast Cancer (0:00) Case: A premenopausal woman in her late 40s with 0.8-cm ER/PR-positive, HER2-negative invasive ductal carcinoma (IDC) with 2 positive nodes and an Oncotype DX® Recurrence Score® (RS) of 9 — Ranju Gupta, MD (13:59) Case: A premenopausal woman in her early 40s with 5-cm ER/PR-positive, HER2-negative Grade I IDC — Nick Leasure, MD (17:43) Case: A woman in her early 70s with ER/PR-positive, HER2-low (IHC 1+) metastatic IDC receiving T-DXd with mixed response — Gigi Chen, MD (38:38) Case: A woman in her late 40s with multicentric triple-negative breast cancer with a gBRCA1 mutation who receives treatment per KEYNOTE-522 and achieves a complete remission with neoadjuvant treatment — Zanetta S Lamar, MD (44:27) Case: A premenopausal woman in her early 50s with bilateral ER/PR-positive, HER2-negative, IDC with PALB2 mutation and multiple, bilateral positive nodes — William R Mitchell, MD (46:44) Case: A woman in her mid 30s who is 18 weeks pregnant and is diagnosed with ER/PR-positive, HER2-negative IDC and an Oncotype DX RS of 17 — Alan B Astrow, MD (50:48) Case: A woman in her late 40s with ER/PR-positive, HER2-negative metastatic breast cancer with NTRK mutation and CNS involvement who receives entrectinib — Rahul Gosain, MD (52:55) Case: A woman in her early 60s with ER/PR-positive, HER2-negative metaplastic breast cancer with an Oncotype DX RS of 51 who has received an adjuvant aromatase inhibitor for 16 years — Rajalaxmi McKenna, MD (56:04) CME information and select publications